{
  "metadata": {
    "graph_path": "./logic_graph.png",
    "num_solutions": 7,
    "family_stats": {
      "1": {
        "core": 1,
        "branch": 1
      },
      "2": {
        "core": 1,
        "branch": 2
      },
      "3": {
        "core": 1,
        "branch": 1
      }
    }
  },
  "knowledge_base": {
    "rules": [
      {
        "id": "Rule1",
        "formal": "(A10 → ¬A11)",
        "prover9_expression": "(manufacturing_process_approved(Drug_Candidate_A) -> -mass_production_begun(Drug_Candidate_A))",
        "natural": "If the manufacturing process for Drug Candidate A is approved, then mass production of Drug Candidate A does not begin."
      },
      {
        "id": "Rule2",
        "formal": "(A15 → A14)",
        "prover9_expression": "(patent_approved(Substance_Z) -> patent_filed(Substance_Z))",
        "natural": "If the patent for Substance Z is approved, then a patent for Substance Z is filed."
      },
      {
        "id": "Rule3",
        "formal": "(A18 ∨ ¬A10)",
        "prover9_expression": "(market_release(Drug_Candidate_A) | -manufacturing_process_approved(Drug_Candidate_A))",
        "natural": "Either Drug Candidate A is released to the market or the manufacturing process for Drug Candidate A is not approved."
      },
      {
        "id": "Rule4",
        "formal": "(A19 → ¬A18)",
        "prover9_expression": "(competitor_launch(Drug_X) -> -market_release(Drug_Candidate_A))",
        "natural": "If Competitor Drug X is launched, then Drug Candidate A is not released to the market."
      },
      {
        "id": "Rule5",
        "formal": "(A19 ∨ A20)",
        "prover9_expression": "(competitor_launch(Drug_X) | generic_version_available(Drug_Candidate_A))",
        "natural": "Either Competitor Drug X is launched or a generic version of Drug Candidate A becomes available."
      },
      {
        "id": "Rule6",
        "formal": "(A2 → A3)",
        "prover9_expression": "(clinical_trial_initiated(Drug_Candidate_A) -> clinical_trial_completed(Drug_Candidate_A))",
        "natural": "If clinical trials for Drug Candidate A are initiated, then clinical trials for Drug Candidate A are completed."
      },
      {
        "id": "Rule7",
        "formal": "(A2 ∨ (¬G → A1))",
        "prover9_expression": "(clinical_trial_initiated(Drug_Candidate_A) | (-grant_awarded(Substance_Z) -> research_funded(Project_X)))",
        "natural": "Either clinical trials for Drug Candidate A are initiated or, if a grant for Substance Z is not awarded, then Project X receives research funding."
      },
      {
        "id": "Rule8",
        "formal": "(A22 → A21)",
        "prover9_expression": "(sales_decline(Drug_Candidate_A) -> price_reduction(Drug_Candidate_A))",
        "natural": "If sales of Drug Candidate A decline, then the price of Drug Candidate A is reduced."
      },
      {
        "id": "Rule9",
        "formal": "(A22 ∨ A23)",
        "prover9_expression": "(sales_decline(Drug_Candidate_A) | market_share_loss(Drug_Candidate_A))",
        "natural": "Either sales of Drug Candidate A decline or Drug Candidate A loses market share."
      },
      {
        "id": "Rule10",
        "formal": "(A23 → (A20 → ¬A18))",
        "prover9_expression": "(market_share_loss(Drug_Candidate_A) -> (generic_version_available(Drug_Candidate_A) -> -market_release(Drug_Candidate_A)))",
        "natural": "If Drug Candidate A loses market share, then, should a generic version of Drug Candidate A become available, Drug Candidate A is not released to the market."
      },
      {
        "id": "Rule11",
        "formal": "(A24 → (A8 ∨ A9))",
        "prover9_expression": "(research_shifted(Disease_Y) -> (human_trials_initiated(Drug_Candidate_B) | alternative_formulation_developed(Drug_Candidate_B)))",
        "natural": "If research focus shifts to Disease Y, then either human trials for Drug Candidate B are initiated or an alternative formulation for Drug Candidate B is developed."
      },
      {
        "id": "Rule12",
        "formal": "(A25 → (A8 ∨ A9))",
        "prover9_expression": "(new_indication_studied(Drug_Candidate_A) -> (human_trials_initiated(Drug_Candidate_B) | alternative_formulation_developed(Drug_Candidate_B)))",
        "natural": "If a new indication for Drug Candidate A is studied, then either human trials for Drug Candidate B are initiated or an alternative formulation for Drug Candidate B is developed."
      },
      {
        "id": "Rule13",
        "formal": "(A26 → A24)",
        "prover9_expression": "(breakthrough_finding(Disease_Y) -> research_shifted(Disease_Y))",
        "natural": "If a breakthrough finding for Disease Y occurs, then research focus shifts to Disease Y."
      },
      {
        "id": "Rule14",
        "formal": "(A26 ∨ A27)",
        "prover9_expression": "(breakthrough_finding(Disease_Y) | existing_drug_repurposed(Drug_Candidate_A))",
        "natural": "Either a breakthrough finding for Disease Y occurs or Drug Candidate A is repurposed for an existing condition."
      },
      {
        "id": "Rule15",
        "formal": "(A28 ∨ (A27 → A25))",
        "prover9_expression": "(partnership_formed(Company_B) | (existing_drug_repurposed(Drug_Candidate_A) -> new_indication_studied(Drug_Candidate_A)))",
        "natural": "Either a partnership with Company B is formed or, if Drug Candidate A is repurposed for an existing condition, then a new indication for Drug Candidate A is studied."
      },
      {
        "id": "Rule16",
        "formal": "(A29 ∨ ¬A28)",
        "prover9_expression": "(licensing_agreement_signed(Company_B) | -partnership_formed(Company_B))",
        "natural": "Either a licensing agreement with Company B is signed or a partnership with Company B is not formed."
      },
      {
        "id": "Rule17",
        "formal": "(A3 → A5)",
        "prover9_expression": "(clinical_trial_completed(Drug_Candidate_A) -> side_effects_observed(Drug_Candidate_A))",
        "natural": "If clinical trials for Drug Candidate A are completed, then side effects for Drug Candidate A are observed."
      },
      {
        "id": "Rule18",
        "formal": "(A3 → ¬A4)",
        "prover9_expression": "(clinical_trial_completed(Drug_Candidate_A) -> -regulatory_approval_granted(Drug_Candidate_A))",
        "natural": "If clinical trials for Drug Candidate A are completed, then regulatory approval for Drug Candidate A is not granted."
      },
      {
        "id": "Rule19",
        "formal": "(A30 → (A13 → G))",
        "prover9_expression": "(research_published(Substance_Z) -> (compound_discovered(Substance_Z) -> grant_awarded(Substance_Z)))",
        "natural": "If research on Substance Z is published, then, if Substance Z is discovered, a grant for Substance Z is awarded."
      },
      {
        "id": "Rule20",
        "formal": "(A31 → (A13 → G))",
        "prover9_expression": "(conference_presentation(Substance_Z) -> (compound_discovered(Substance_Z) -> grant_awarded(Substance_Z)))",
        "natural": "If a conference presentation on Substance Z is made, then, if Substance Z is discovered, a grant for Substance Z is awarded."
      },
      {
        "id": "Rule21",
        "formal": "(A32 → (A30 ∨ A31))",
        "prover9_expression": "(peer_review_completed(Substance_Z) -> (research_published(Substance_Z) | conference_presentation(Substance_Z)))",
        "natural": "If peer review for Substance Z is completed, then either research on Substance Z is published or a conference presentation on Substance Z is made."
      },
      {
        "id": "Rule22",
        "formal": "(A33 → A34)",
        "prover9_expression": "(patent_challenged(Substance_Z) -> legal_dispute_initiated(Substance_Z))",
        "natural": "If the patent for Substance Z is challenged, then a legal dispute over Substance Z is initiated."
      },
      {
        "id": "Rule23",
        "formal": "(A33 → ¬A34)",
        "prover9_expression": "(patent_challenged(Substance_Z) -> -legal_dispute_initiated(Substance_Z))",
        "natural": "If the patent for Substance Z is challenged, then a legal dispute over Substance Z is not initiated."
      },
      {
        "id": "Rule24",
        "formal": "(A5 → A4)",
        "prover9_expression": "(side_effects_observed(Drug_Candidate_A) -> regulatory_approval_granted(Drug_Candidate_A))",
        "natural": "If side effects for Drug Candidate A are observed, then regulatory approval for Drug Candidate A is granted."
      },
      {
        "id": "Rule25",
        "formal": "(A6 → A7)",
        "prover9_expression": "(preclinical_stage_initiated(Drug_Candidate_B) -> animal_testing_completed(Drug_Candidate_B))",
        "natural": "If the preclinical stage for Drug Candidate B is initiated, then animal testing for Drug Candidate B is completed."
      },
      {
        "id": "Rule26",
        "formal": "(A6 ∨ G)",
        "prover9_expression": "(preclinical_stage_initiated(Drug_Candidate_B) | grant_awarded(Substance_Z))",
        "natural": "Either the preclinical stage for Drug Candidate B is initiated or a grant for Substance Z is awarded."
      },
      {
        "id": "Rule27",
        "formal": "(A8 → ¬A7)",
        "prover9_expression": "(human_trials_initiated(Drug_Candidate_B) -> -animal_testing_completed(Drug_Candidate_B))",
        "natural": "If human trials for Drug Candidate B are initiated, then animal testing for Drug Candidate B is not completed."
      },
      {
        "id": "Rule28",
        "formal": "(A9 → ¬A7)",
        "prover9_expression": "(alternative_formulation_developed(Drug_Candidate_B) -> -animal_testing_completed(Drug_Candidate_B))",
        "natural": "If an alternative formulation for Drug Candidate B is developed, then animal testing for Drug Candidate B is not completed."
      },
      {
        "id": "Rule29",
        "formal": "(¬(A10 → A11) → A12)",
        "prover9_expression": "(-(manufacturing_process_approved(Drug_Candidate_A) -> mass_production_begun(Drug_Candidate_A)) -> manufacturing_process_revised(Drug_Candidate_A))",
        "natural": "If it is not the case that the manufacturing process for Drug Candidate A being approved leads to mass production of Drug Candidate A beginning, then the manufacturing process for Drug Candidate A is revised."
      },
      {
        "id": "Rule30",
        "formal": "(¬(A13 → G) → A15)",
        "prover9_expression": "(-(compound_discovered(Substance_Z) -> grant_awarded(Substance_Z)) -> patent_approved(Substance_Z))",
        "natural": "If it is not the case that Substance Z being discovered leads to a grant for Substance Z being awarded, then the patent for Substance Z is approved."
      },
      {
        "id": "Rule31",
        "formal": "(¬(A13 → G) → ¬A14)",
        "prover9_expression": "(-(compound_discovered(Substance_Z) -> grant_awarded(Substance_Z)) -> -patent_filed(Substance_Z))",
        "natural": "If it is not the case that Substance Z being discovered leads to a grant for Substance Z being awarded, then a patent for Substance Z is not filed."
      },
      {
        "id": "Rule32",
        "formal": "(¬(A3 → A4) → A16)",
        "prover9_expression": "(-(clinical_trial_completed(Drug_Candidate_A) -> regulatory_approval_granted(Drug_Candidate_A)) -> clinical_trial_suspended(Drug_Candidate_A))",
        "natural": "If it is not the case that clinical trials for Drug Candidate A being completed leads to regulatory approval for Drug Candidate A being granted, then clinical trials for Drug Candidate A are suspended."
      },
      {
        "id": "Rule33",
        "formal": "(¬(A8 ∨ A9) → A10)",
        "prover9_expression": "(-(human_trials_initiated(Drug_Candidate_B) | alternative_formulation_developed(Drug_Candidate_B)) -> manufacturing_process_approved(Drug_Candidate_A))",
        "natural": "If neither human trials for Drug Candidate B are initiated nor an alternative formulation for Drug Candidate B is developed, then the manufacturing process for Drug Candidate A is approved."
      },
      {
        "id": "Rule34",
        "formal": "(¬(¬(A3 → A4) → ¬A16) → A17)",
        "prover9_expression": "(-(-(clinical_trial_completed(Drug_Candidate_A) -> regulatory_approval_granted(Drug_Candidate_A)) -> -clinical_trial_suspended(Drug_Candidate_A)) -> investigation_launched(Drug_Candidate_A))",
        "natural": "If it is not the case that the failure of clinical trials for Drug Candidate A being completed to lead to regulatory approval for Drug Candidate A being granted results in clinical trials for Drug Candidate A not being suspended, then an investigation into Drug Candidate A is launched."
      },
      {
        "id": "Rule35",
        "formal": "(¬A32 → A33)",
        "prover9_expression": "(-peer_review_completed(Substance_Z) -> patent_challenged(Substance_Z))",
        "natural": "If peer review for Substance Z is not completed, then the patent for Substance Z is challenged."
      }
    ],
    "facts": [
      {
        "id": "Fact1",
        "formal": "A13",
        "prover9_expression": "compound_discovered(Substance_Z)",
        "natural": "Substance Z is discovered."
      },
      {
        "id": "Fact2",
        "formal": "¬A1",
        "prover9_expression": "-research_funded(Project_X)",
        "natural": "Project X does not receive research funding."
      },
      {
        "id": "Fact3",
        "formal": "¬A12",
        "prover9_expression": "-manufacturing_process_revised(Drug_Candidate_A)",
        "natural": "The manufacturing process for Drug Candidate A is not revised."
      },
      {
        "id": "Fact4",
        "formal": "¬A17",
        "prover9_expression": "-investigation_launched(Drug_Candidate_A)",
        "natural": "An investigation into Drug Candidate A is not launched."
      },
      {
        "id": "Fact5",
        "formal": "¬A21",
        "prover9_expression": "-price_reduction(Drug_Candidate_A)",
        "natural": "The price of Drug Candidate A is not reduced."
      },
      {
        "id": "Fact6",
        "formal": "¬A29",
        "prover9_expression": "-licensing_agreement_signed(Company_B)",
        "natural": "A licensing agreement with Company B is not signed."
      }
    ]
  },
  "target": {
    "formal": "G",
    "prover9": "G",
    "prover9_expression": "grant_awarded(Substance_Z)",
    "natural": "A grant for Substance Z is awarded."
  },
  "solutions": [
    {
      "id": 1,
      "family_id": 1,
      "path_type": "core",
      "branch_from": null,
      "steps": [
        {
          "step_number": 1,
          "rule_applied": "HS",
          "premises_used": [
            "(A3 -> A5)",
            "(A5 -> A4)"
          ],
          "conclusion": "(A3 -> A4)",
          "natural": "If clinical trials for Drug Candidate A are completed, then regulatory approval for Drug Candidate A is granted."
        },
        {
          "step_number": 2,
          "rule_applied": "RAA",
          "premises_used": [
            "(A3 -> A4)",
            "(A3 -> -A4)"
          ],
          "conclusion": "-A3",
          "natural": "Clinical trials for Drug Candidate A are not completed."
        },
        {
          "step_number": 3,
          "rule_applied": "MT",
          "premises_used": [
            "(A2 -> A3)",
            "-A3"
          ],
          "conclusion": "-A2",
          "natural": "Clinical trials for Drug Candidate A are not initiated."
        },
        {
          "step_number": 4,
          "rule_applied": "DS",
          "premises_used": [
            "(A2 | (-G -> A1))",
            "-A2"
          ],
          "conclusion": "(-G -> A1)",
          "natural": "If a grant for Substance Z is not awarded, then Project X receives research funding."
        },
        {
          "step_number": 5,
          "rule_applied": "MT",
          "premises_used": [
            "(-G -> A1)",
            "-A1"
          ],
          "conclusion": "G",
          "natural": "A grant for Substance Z is awarded."
        }
      ]
    },
    {
      "id": 2,
      "family_id": 2,
      "path_type": "core",
      "branch_from": null,
      "steps": [
        {
          "step_number": 1,
          "rule_applied": "MT",
          "premises_used": [
            "(-(A10 -> A11) -> A12)",
            "-A12"
          ],
          "conclusion": "(A10 -> A11)",
          "natural": "If the manufacturing process for Drug Candidate A is approved, then mass production of Drug Candidate A begins."
        },
        {
          "step_number": 2,
          "rule_applied": "RAA",
          "premises_used": [
            "(A10 -> A11)",
            "(A10 -> -A11)"
          ],
          "conclusion": "-A10",
          "natural": "The manufacturing process for Drug Candidate A is not approved."
        },
        {
          "step_number": 3,
          "rule_applied": "MT",
          "premises_used": [
            "(-(A8 | A9) -> A10)",
            "-A10"
          ],
          "conclusion": "(A8 | A9)",
          "natural": "Either human trials for Drug Candidate B are initiated or an alternative formulation for Drug Candidate B is developed."
        },
        {
          "step_number": 4,
          "rule_applied": "DE",
          "premises_used": [
            "(A8 | A9)",
            "(A8 -> -A7)",
            "(A9 -> -A7)"
          ],
          "conclusion": "-A7",
          "natural": "Animal testing for Drug Candidate B is not completed."
        },
        {
          "step_number": 5,
          "rule_applied": "MT",
          "premises_used": [
            "(A6 -> A7)",
            "-A7"
          ],
          "conclusion": "-A6",
          "natural": "The preclinical stage for Drug Candidate B is not initiated."
        },
        {
          "step_number": 6,
          "rule_applied": "DS",
          "premises_used": [
            "(A6 | G)",
            "-A6"
          ],
          "conclusion": "G",
          "natural": "A grant for Substance Z is awarded."
        }
      ]
    },
    {
      "id": 3,
      "family_id": 3,
      "path_type": "core",
      "branch_from": null,
      "steps": [
        {
          "step_number": 1,
          "rule_applied": "HS",
          "premises_used": [
            "(-(A13 -> G) -> A15)",
            "(A15 -> A14)"
          ],
          "conclusion": "(-(A13 -> G) -> A14)",
          "natural": "If it is not the case that Substance Z being discovered leads to a grant for Substance Z being awarded, then a patent for Substance Z is filed."
        },
        {
          "step_number": 2,
          "rule_applied": "RAA",
          "premises_used": [
            "(-(A13 -> G) -> A14)",
            "(-(A13 -> G) -> -A14)"
          ],
          "conclusion": "(A13 -> G)",
          "natural": "If Substance Z is discovered, then a grant for Substance Z is awarded."
        },
        {
          "step_number": 3,
          "rule_applied": "MP",
          "premises_used": [
            "(A13 -> G)",
            "A13"
          ],
          "conclusion": "G",
          "natural": "A grant for Substance Z is awarded."
        }
      ]
    },
    {
      "id": 4,
      "family_id": 1,
      "path_type": "branch",
      "branch_from": 0,
      "steps": [
        {
          "step_number": 1,
          "rule_applied": "MT",
          "premises_used": [
            "(-(-(A3 -> A4) -> -A16) -> A17)",
            "-A17"
          ],
          "conclusion": "(-(A3 -> A4) -> -A16)",
          "natural": "If it is not the case that clinical trials for Drug Candidate A being completed leads to regulatory approval for Drug Candidate A being granted, then clinical trials for Drug Candidate A are not suspended."
        },
        {
          "step_number": 2,
          "rule_applied": "RAA",
          "premises_used": [
            "(-(A3 -> A4) -> A16)",
            "(-(A3 -> A4) -> -A16)"
          ],
          "conclusion": "(A3 -> A4)",
          "natural": "If clinical trials for Drug Candidate A are completed, then regulatory approval for Drug Candidate A is granted."
        },
        {
          "step_number": 3,
          "rule_applied": "RAA",
          "premises_used": [
            "(A3 -> A4)",
            "(A3 -> -A4)"
          ],
          "conclusion": "-A3",
          "natural": "Clinical trials for Drug Candidate A are not completed."
        },
        {
          "step_number": 4,
          "rule_applied": "MT",
          "premises_used": [
            "(A2 -> A3)",
            "-A3"
          ],
          "conclusion": "-A2",
          "natural": "Clinical trials for Drug Candidate A are not initiated."
        },
        {
          "step_number": 5,
          "rule_applied": "DS",
          "premises_used": [
            "(A2 | (-G -> A1))",
            "-A2"
          ],
          "conclusion": "(-G -> A1)",
          "natural": "If a grant for Substance Z is not awarded, then Project X receives research funding."
        },
        {
          "step_number": 6,
          "rule_applied": "MT",
          "premises_used": [
            "(-G -> A1)",
            "-A1"
          ],
          "conclusion": "G",
          "natural": "A grant for Substance Z is awarded."
        }
      ]
    },
    {
      "id": 5,
      "family_id": 2,
      "path_type": "branch",
      "branch_from": 1,
      "steps": [
        {
          "step_number": 1,
          "rule_applied": "CD",
          "premises_used": [
            "(A22 -> A21)",
            "(A23 -> (A20 -> -A18))",
            "(A22 | A23)"
          ],
          "conclusion": "(A21 | (A20 -> -A18))",
          "natural": "Either the price of Drug Candidate A is reduced or, if a generic version of Drug Candidate A becomes available, then Drug Candidate A is not released to the market."
        },
        {
          "step_number": 2,
          "rule_applied": "DS",
          "premises_used": [
            "(A21 | (A20 -> -A18))",
            "-A21"
          ],
          "conclusion": "(A20 -> -A18)",
          "natural": "If a generic version of Drug Candidate A becomes available, then Drug Candidate A is not released to the market."
        },
        {
          "step_number": 3,
          "rule_applied": "DE",
          "premises_used": [
            "(A19 | A20)",
            "(A19 -> -A18)",
            "(A20 -> -A18)"
          ],
          "conclusion": "-A18",
          "natural": "Drug Candidate A is not released to the market."
        },
        {
          "step_number": 4,
          "rule_applied": "DS",
          "premises_used": [
            "(A18 | -A10)",
            "-A18"
          ],
          "conclusion": "-A10",
          "natural": "The manufacturing process for Drug Candidate A is not approved."
        },
        {
          "step_number": 5,
          "rule_applied": "MT",
          "premises_used": [
            "(-(A8 | A9) -> A10)",
            "-A10"
          ],
          "conclusion": "(A8 | A9)",
          "natural": "Either human trials for Drug Candidate B are initiated or an alternative formulation for Drug Candidate B is developed."
        },
        {
          "step_number": 6,
          "rule_applied": "DE",
          "premises_used": [
            "(A8 | A9)",
            "(A8 -> -A7)",
            "(A9 -> -A7)"
          ],
          "conclusion": "-A7",
          "natural": "Animal testing for Drug Candidate B is not completed."
        },
        {
          "step_number": 7,
          "rule_applied": "MT",
          "premises_used": [
            "(A6 -> A7)",
            "-A7"
          ],
          "conclusion": "-A6",
          "natural": "The preclinical stage for Drug Candidate B is not initiated."
        },
        {
          "step_number": 8,
          "rule_applied": "DS",
          "premises_used": [
            "(A6 | G)",
            "-A6"
          ],
          "conclusion": "G",
          "natural": "A grant for Substance Z is awarded."
        }
      ]
    },
    {
      "id": 6,
      "family_id": 2,
      "path_type": "branch",
      "branch_from": 2,
      "steps": [
        {
          "step_number": 1,
          "rule_applied": "DS",
          "premises_used": [
            "(A29 | -A28)",
            "-A29"
          ],
          "conclusion": "-A28",
          "natural": "A partnership with Company B is not formed."
        },
        {
          "step_number": 2,
          "rule_applied": "DS",
          "premises_used": [
            "(A28 | (A27 -> A25))",
            "-A28"
          ],
          "conclusion": "(A27 -> A25)",
          "natural": "If Drug Candidate A is repurposed for an existing condition, then a new indication for Drug Candidate A is studied."
        },
        {
          "step_number": 3,
          "rule_applied": "CD",
          "premises_used": [
            "(A26 -> A24)",
            "(A27 -> A25)",
            "(A26 | A27)"
          ],
          "conclusion": "(A24 | A25)",
          "natural": "Either research focus shifts to Disease Y or a new indication for Drug Candidate A is studied."
        },
        {
          "step_number": 4,
          "rule_applied": "DE",
          "premises_used": [
            "(A24 | A25)",
            "(A24 -> (A8 | A9))",
            "(A25 -> (A8 | A9))"
          ],
          "conclusion": "(A8 | A9)",
          "natural": "Either human trials for Drug Candidate B are initiated or an alternative formulation for Drug Candidate B is developed."
        },
        {
          "step_number": 5,
          "rule_applied": "DE",
          "premises_used": [
            "(A8 | A9)",
            "(A8 -> -A7)",
            "(A9 -> -A7)"
          ],
          "conclusion": "-A7",
          "natural": "Animal testing for Drug Candidate B is not completed."
        },
        {
          "step_number": 6,
          "rule_applied": "MT",
          "premises_used": [
            "(A6 -> A7)",
            "-A7"
          ],
          "conclusion": "-A6",
          "natural": "The preclinical stage for Drug Candidate B is not initiated."
        },
        {
          "step_number": 7,
          "rule_applied": "DS",
          "premises_used": [
            "(A6 | G)",
            "-A6"
          ],
          "conclusion": "G",
          "natural": "A grant for Substance Z is awarded."
        }
      ]
    },
    {
      "id": 7,
      "family_id": 3,
      "path_type": "branch",
      "branch_from": 1,
      "steps": [
        {
          "step_number": 1,
          "rule_applied": "RAA",
          "premises_used": [
            "(A33 -> A34)",
            "(A33 -> -A34)"
          ],
          "conclusion": "-A33",
          "natural": "The patent for Substance Z is not challenged."
        },
        {
          "step_number": 2,
          "rule_applied": "MT",
          "premises_used": [
            "(-A32 -> A33)",
            "-A33"
          ],
          "conclusion": "A32",
          "natural": "Peer review for Substance Z is completed."
        },
        {
          "step_number": 3,
          "rule_applied": "MP",
          "premises_used": [
            "(A32 -> (A30 | A31))",
            "A32"
          ],
          "conclusion": "(A30 | A31)",
          "natural": "Either research on Substance Z is published or a conference presentation on Substance Z is made."
        },
        {
          "step_number": 4,
          "rule_applied": "DE",
          "premises_used": [
            "(A30 | A31)",
            "(A30 -> (A13 -> G))",
            "(A31 -> (A13 -> G))"
          ],
          "conclusion": "(A13 -> G)",
          "natural": "If Substance Z is discovered, then a grant for Substance Z is awarded."
        },
        {
          "step_number": 5,
          "rule_applied": "MP",
          "premises_used": [
            "(A13 -> G)",
            "A13"
          ],
          "conclusion": "G",
          "natural": "A grant for Substance Z is awarded."
        }
      ]
    }
  ],
  "translations": {
    "atomic_facts": {
      "A1": "research_funded(Project_X)",
      "A2": "clinical_trial_initiated(Drug_Candidate_A)",
      "A3": "clinical_trial_completed(Drug_Candidate_A)",
      "A4": "regulatory_approval_granted(Drug_Candidate_A)",
      "A5": "side_effects_observed(Drug_Candidate_A)",
      "A6": "preclinical_stage_initiated(Drug_Candidate_B)",
      "A7": "animal_testing_completed(Drug_Candidate_B)",
      "A8": "human_trials_initiated(Drug_Candidate_B)",
      "A9": "alternative_formulation_developed(Drug_Candidate_B)",
      "A10": "manufacturing_process_approved(Drug_Candidate_A)",
      "A11": "mass_production_begun(Drug_Candidate_A)",
      "A12": "manufacturing_process_revised(Drug_Candidate_A)",
      "A13": "compound_discovered(Substance_Z)",
      "A14": "patent_filed(Substance_Z)",
      "A15": "patent_approved(Substance_Z)",
      "A16": "clinical_trial_suspended(Drug_Candidate_A)",
      "A17": "investigation_launched(Drug_Candidate_A)",
      "A18": "market_release(Drug_Candidate_A)",
      "A19": "competitor_launch(Drug_X)",
      "A20": "generic_version_available(Drug_Candidate_A)",
      "A21": "price_reduction(Drug_Candidate_A)",
      "A22": "sales_decline(Drug_Candidate_A)",
      "A23": "market_share_loss(Drug_Candidate_A)",
      "A24": "research_shifted(Disease_Y)",
      "A25": "new_indication_studied(Drug_Candidate_A)",
      "A26": "breakthrough_finding(Disease_Y)",
      "A27": "existing_drug_repurposed(Drug_Candidate_A)",
      "A28": "partnership_formed(Company_B)",
      "A29": "licensing_agreement_signed(Company_B)",
      "A30": "research_published(Substance_Z)",
      "A31": "conference_presentation(Substance_Z)",
      "A32": "peer_review_completed(Substance_Z)",
      "A33": "patent_challenged(Substance_Z)",
      "A34": "legal_dispute_initiated(Substance_Z)",
      "G": "grant_awarded(Substance_Z)"
    },
    "natural_facts": {
      "A1": "Project X receives research funding.",
      "A2": "Clinical trials for Drug Candidate A are initiated.",
      "A3": "Clinical trials for Drug Candidate A are completed.",
      "A4": "Regulatory approval for Drug Candidate A is granted.",
      "A5": "Side effects for Drug Candidate A are observed.",
      "A6": "Preclinical stage for Drug Candidate B is initiated.",
      "A7": "Animal testing for Drug Candidate B is completed.",
      "A8": "Human trials for Drug Candidate B are initiated.",
      "A9": "An alternative formulation for Drug Candidate B is developed.",
      "A10": "Manufacturing process for Drug Candidate A is approved.",
      "A11": "Mass production of Drug Candidate A begins.",
      "A12": "Manufacturing process for Drug Candidate A is revised.",
      "A13": "Substance Z is discovered.",
      "A14": "A patent for Substance Z is filed.",
      "A15": "The patent for Substance Z is approved.",
      "A16": "Clinical trials for Drug Candidate A are suspended.",
      "A17": "An investigation into Drug Candidate A is launched.",
      "A18": "Drug Candidate A is released to the market.",
      "A19": "Competitor Drug X is launched.",
      "A20": "A generic version of Drug Candidate A becomes available.",
      "A21": "The price of Drug Candidate A is reduced.",
      "A22": "Sales of Drug Candidate A decline.",
      "A23": "Drug Candidate A loses market share.",
      "A24": "Research focus shifts to Disease Y.",
      "A25": "A new indication for Drug Candidate A is studied.",
      "A26": "A breakthrough finding for Disease Y occurs.",
      "A27": "Drug Candidate A is repurposed for an existing condition.",
      "A28": "A partnership with Company B is formed.",
      "A29": "A licensing agreement with Company B is signed.",
      "A30": "Research on Substance Z is published.",
      "A31": "A conference presentation on Substance Z is made.",
      "A32": "Peer review for Substance Z is completed.",
      "A33": "The patent for Substance Z is challenged.",
      "A34": "A legal dispute over Substance Z is initiated.",
      "G": "A grant for Substance Z is awarded."
    },
    "prover9_expressions": [
      "(manufacturing_process_approved(Drug_Candidate_A) → mass_production_begun(Drug_Candidate_A))",
      "(manufacturing_process_approved(Drug_Candidate_A) → ¬mass_production_begun(Drug_Candidate_A))",
      "(compound_discovered(Substance_Z) → grant_awarded(Substance_Z))",
      "(patent_approved(Substance_Z) → patent_filed(Substance_Z))",
      "(market_release(Drug_Candidate_A) ∨ ¬manufacturing_process_approved(Drug_Candidate_A))",
      "(competitor_launch(Drug_X) → ¬market_release(Drug_Candidate_A))",
      "(competitor_launch(Drug_X) ∨ generic_version_available(Drug_Candidate_A))",
      "(clinical_trial_initiated(Drug_Candidate_A) → clinical_trial_completed(Drug_Candidate_A))",
      "(clinical_trial_initiated(Drug_Candidate_A) ∨ (¬grant_awarded(Substance_Z) → research_funded(Project_X)))",
      "(generic_version_available(Drug_Candidate_A) → ¬market_release(Drug_Candidate_A))",
      "(price_reduction(Drug_Candidate_A) ∨ (generic_version_available(Drug_Candidate_A) → ¬market_release(Drug_Candidate_A)))",
      "(sales_decline(Drug_Candidate_A) → price_reduction(Drug_Candidate_A))",
      "(sales_decline(Drug_Candidate_A) ∨ market_share_loss(Drug_Candidate_A))",
      "(market_share_loss(Drug_Candidate_A) → (generic_version_available(Drug_Candidate_A) → ¬market_release(Drug_Candidate_A)))",
      "(research_shifted(Disease_Y) → (human_trials_initiated(Drug_Candidate_B) ∨ alternative_formulation_developed(Drug_Candidate_B)))",
      "(research_shifted(Disease_Y) ∨ new_indication_studied(Drug_Candidate_A))",
      "(new_indication_studied(Drug_Candidate_A) → (human_trials_initiated(Drug_Candidate_B) ∨ alternative_formulation_developed(Drug_Candidate_B)))",
      "(breakthrough_finding(Disease_Y) → research_shifted(Disease_Y))",
      "(breakthrough_finding(Disease_Y) ∨ existing_drug_repurposed(Drug_Candidate_A))",
      "(existing_drug_repurposed(Drug_Candidate_A) → new_indication_studied(Drug_Candidate_A))",
      "(partnership_formed(Company_B) ∨ (existing_drug_repurposed(Drug_Candidate_A) → new_indication_studied(Drug_Candidate_A)))",
      "(licensing_agreement_signed(Company_B) ∨ ¬partnership_formed(Company_B))",
      "(clinical_trial_completed(Drug_Candidate_A) → regulatory_approval_granted(Drug_Candidate_A))",
      "(clinical_trial_completed(Drug_Candidate_A) → side_effects_observed(Drug_Candidate_A))",
      "(clinical_trial_completed(Drug_Candidate_A) → ¬regulatory_approval_granted(Drug_Candidate_A))",
      "(research_published(Substance_Z) → (compound_discovered(Substance_Z) → grant_awarded(Substance_Z)))",
      "(research_published(Substance_Z) ∨ conference_presentation(Substance_Z))",
      "(conference_presentation(Substance_Z) → (compound_discovered(Substance_Z) → grant_awarded(Substance_Z)))",
      "(peer_review_completed(Substance_Z) → (research_published(Substance_Z) ∨ conference_presentation(Substance_Z)))",
      "(patent_challenged(Substance_Z) → legal_dispute_initiated(Substance_Z))",
      "(patent_challenged(Substance_Z) → ¬legal_dispute_initiated(Substance_Z))",
      "(side_effects_observed(Drug_Candidate_A) → regulatory_approval_granted(Drug_Candidate_A))",
      "(preclinical_stage_initiated(Drug_Candidate_B) → animal_testing_completed(Drug_Candidate_B))",
      "(preclinical_stage_initiated(Drug_Candidate_B) ∨ grant_awarded(Substance_Z))",
      "(human_trials_initiated(Drug_Candidate_B) → ¬animal_testing_completed(Drug_Candidate_B))",
      "(human_trials_initiated(Drug_Candidate_B) ∨ alternative_formulation_developed(Drug_Candidate_B))",
      "(alternative_formulation_developed(Drug_Candidate_B) → ¬animal_testing_completed(Drug_Candidate_B))",
      "(¬(manufacturing_process_approved(Drug_Candidate_A) → mass_production_begun(Drug_Candidate_A)) → manufacturing_process_revised(Drug_Candidate_A))",
      "(¬(compound_discovered(Substance_Z) → grant_awarded(Substance_Z)) → patent_filed(Substance_Z))",
      "(¬(compound_discovered(Substance_Z) → grant_awarded(Substance_Z)) → patent_approved(Substance_Z))",
      "(¬(compound_discovered(Substance_Z) → grant_awarded(Substance_Z)) → ¬patent_filed(Substance_Z))",
      "(¬(clinical_trial_completed(Drug_Candidate_A) → regulatory_approval_granted(Drug_Candidate_A)) → clinical_trial_suspended(Drug_Candidate_A))",
      "(¬(clinical_trial_completed(Drug_Candidate_A) → regulatory_approval_granted(Drug_Candidate_A)) → ¬clinical_trial_suspended(Drug_Candidate_A))",
      "(¬(human_trials_initiated(Drug_Candidate_B) ∨ alternative_formulation_developed(Drug_Candidate_B)) → manufacturing_process_approved(Drug_Candidate_A))",
      "(¬(¬(clinical_trial_completed(Drug_Candidate_A) → regulatory_approval_granted(Drug_Candidate_A)) → ¬clinical_trial_suspended(Drug_Candidate_A)) → investigation_launched(Drug_Candidate_A))",
      "(¬peer_review_completed(Substance_Z) → patent_challenged(Substance_Z))",
      "(¬grant_awarded(Substance_Z) → research_funded(Project_X))",
      "compound_discovered(Substance_Z)",
      "peer_review_completed(Substance_Z)",
      "grant_awarded(Substance_Z)",
      "¬research_funded(Project_X)",
      "¬manufacturing_process_approved(Drug_Candidate_A)",
      "¬manufacturing_process_revised(Drug_Candidate_A)",
      "¬investigation_launched(Drug_Candidate_A)",
      "¬market_release(Drug_Candidate_A)",
      "¬clinical_trial_initiated(Drug_Candidate_A)",
      "¬price_reduction(Drug_Candidate_A)",
      "¬partnership_formed(Company_B)",
      "¬licensing_agreement_signed(Company_B)",
      "¬clinical_trial_completed(Drug_Candidate_A)",
      "¬patent_challenged(Substance_Z)",
      "¬preclinical_stage_initiated(Drug_Candidate_B)",
      "¬animal_testing_completed(Drug_Candidate_B)"
    ],
    "natural_expressions": [
      "If the manufacturing process for Drug Candidate A is approved, then mass production of Drug Candidate A begins.",
      "If the manufacturing process for Drug Candidate A is approved, then mass production of Drug Candidate A does not begin.",
      "If Substance Z is discovered, then a grant for Substance Z is awarded.",
      "If the patent for Substance Z is approved, then a patent for Substance Z is filed.",
      "Either Drug Candidate A is released to the market or the manufacturing process for Drug Candidate A is not approved.",
      "If Competitor Drug X is launched, then Drug Candidate A is not released to the market.",
      "Either Competitor Drug X is launched or a generic version of Drug Candidate A becomes available.",
      "If clinical trials for Drug Candidate A are initiated, then clinical trials for Drug Candidate A are completed.",
      "Either clinical trials for Drug Candidate A are initiated or, if a grant for Substance Z is not awarded, then Project X receives research funding.",
      "If a generic version of Drug Candidate A becomes available, then Drug Candidate A is not released to the market.",
      "Either the price of Drug Candidate A is reduced or, if a generic version of Drug Candidate A becomes available, then Drug Candidate A is not released to the market.",
      "If sales of Drug Candidate A decline, then the price of Drug Candidate A is reduced.",
      "Either sales of Drug Candidate A decline or Drug Candidate A loses market share.",
      "If Drug Candidate A loses market share, then, should a generic version of Drug Candidate A become available, Drug Candidate A is not released to the market.",
      "If research focus shifts to Disease Y, then either human trials for Drug Candidate B are initiated or an alternative formulation for Drug Candidate B is developed.",
      "Either research focus shifts to Disease Y or a new indication for Drug Candidate A is studied.",
      "If a new indication for Drug Candidate A is studied, then either human trials for Drug Candidate B are initiated or an alternative formulation for Drug Candidate B is developed.",
      "If a breakthrough finding for Disease Y occurs, then research focus shifts to Disease Y.",
      "Either a breakthrough finding for Disease Y occurs or Drug Candidate A is repurposed for an existing condition.",
      "If Drug Candidate A is repurposed for an existing condition, then a new indication for Drug Candidate A is studied.",
      "Either a partnership with Company B is formed or, if Drug Candidate A is repurposed for an existing condition, then a new indication for Drug Candidate A is studied.",
      "Either a licensing agreement with Company B is signed or a partnership with Company B is not formed.",
      "If clinical trials for Drug Candidate A are completed, then regulatory approval for Drug Candidate A is granted.",
      "If clinical trials for Drug Candidate A are completed, then side effects for Drug Candidate A are observed.",
      "If clinical trials for Drug Candidate A are completed, then regulatory approval for Drug Candidate A is not granted.",
      "If research on Substance Z is published, then, if Substance Z is discovered, a grant for Substance Z is awarded.",
      "Either research on Substance Z is published or a conference presentation on Substance Z is made.",
      "If a conference presentation on Substance Z is made, then, if Substance Z is discovered, a grant for Substance Z is awarded.",
      "If peer review for Substance Z is completed, then either research on Substance Z is published or a conference presentation on Substance Z is made.",
      "If the patent for Substance Z is challenged, then a legal dispute over Substance Z is initiated.",
      "If the patent for Substance Z is challenged, then a legal dispute over Substance Z is not initiated.",
      "If side effects for Drug Candidate A are observed, then regulatory approval for Drug Candidate A is granted.",
      "If the preclinical stage for Drug Candidate B is initiated, then animal testing for Drug Candidate B is completed.",
      "Either the preclinical stage for Drug Candidate B is initiated or a grant for Substance Z is awarded.",
      "If human trials for Drug Candidate B are initiated, then animal testing for Drug Candidate B is not completed.",
      "Either human trials for Drug Candidate B are initiated or an alternative formulation for Drug Candidate B is developed.",
      "If an alternative formulation for Drug Candidate B is developed, then animal testing for Drug Candidate B is not completed.",
      "If it is not the case that the manufacturing process for Drug Candidate A being approved leads to mass production of Drug Candidate A beginning, then the manufacturing process for Drug Candidate A is revised.",
      "If it is not the case that Substance Z being discovered leads to a grant for Substance Z being awarded, then a patent for Substance Z is filed.",
      "If it is not the case that Substance Z being discovered leads to a grant for Substance Z being awarded, then the patent for Substance Z is approved.",
      "If it is not the case that Substance Z being discovered leads to a grant for Substance Z being awarded, then a patent for Substance Z is not filed.",
      "If it is not the case that clinical trials for Drug Candidate A being completed leads to regulatory approval for Drug Candidate A being granted, then clinical trials for Drug Candidate A are suspended.",
      "If it is not the case that clinical trials for Drug Candidate A being completed leads to regulatory approval for Drug Candidate A being granted, then clinical trials for Drug Candidate A are not suspended.",
      "If neither human trials for Drug Candidate B are initiated nor an alternative formulation for Drug Candidate B is developed, then the manufacturing process for Drug Candidate A is approved.",
      "If it is not the case that the failure of clinical trials for Drug Candidate A being completed to lead to regulatory approval for Drug Candidate A being granted results in clinical trials for Drug Candidate A not being suspended, then an investigation into Drug Candidate A is launched.",
      "If peer review for Substance Z is not completed, then the patent for Substance Z is challenged.",
      "If a grant for Substance Z is not awarded, then Project X receives research funding.",
      "Substance Z is discovered.",
      "Peer review for Substance Z is completed.",
      "A grant for Substance Z is awarded.",
      "Project X does not receive research funding.",
      "The manufacturing process for Drug Candidate A is not approved.",
      "The manufacturing process for Drug Candidate A is not revised.",
      "An investigation into Drug Candidate A is not launched.",
      "Drug Candidate A is not released to the market.",
      "Clinical trials for Drug Candidate A are not initiated.",
      "The price of Drug Candidate A is not reduced.",
      "A partnership with Company B is not formed.",
      "A licensing agreement with Company B is not signed.",
      "Clinical trials for Drug Candidate A are not completed.",
      "The patent for Substance Z is not challenged.",
      "The preclinical stage for Drug Candidate B is not initiated.",
      "Animal testing for Drug Candidate B is not completed."
    ],
    "node_mappings": {
      "(A10 → A11)": {
        "formal": "(A10 → A11)",
        "prover9": "(A10 -> A11)",
        "prover9_expression": "(manufacturing_process_approved(Drug_Candidate_A) -> mass_production_begun(Drug_Candidate_A))",
        "natural": "If the manufacturing process for Drug Candidate A is approved, then mass production of Drug Candidate A begins."
      },
      "(A10 → ¬A11)": {
        "formal": "(A10 → ¬A11)",
        "prover9": "(A10 -> -A11)",
        "prover9_expression": "(manufacturing_process_approved(Drug_Candidate_A) -> -mass_production_begun(Drug_Candidate_A))",
        "natural": "If the manufacturing process for Drug Candidate A is approved, then mass production of Drug Candidate A does not begin."
      },
      "(A13 → G)": {
        "formal": "(A13 → G)",
        "prover9": "(A13 -> G)",
        "prover9_expression": "(compound_discovered(Substance_Z) -> grant_awarded(Substance_Z))",
        "natural": "If Substance Z is discovered, then a grant for Substance Z is awarded."
      },
      "(A15 → A14)": {
        "formal": "(A15 → A14)",
        "prover9": "(A15 -> A14)",
        "prover9_expression": "(patent_approved(Substance_Z) -> patent_filed(Substance_Z))",
        "natural": "If the patent for Substance Z is approved, then a patent for Substance Z is filed."
      },
      "(A18 ∨ ¬A10)": {
        "formal": "(A18 ∨ ¬A10)",
        "prover9": "(A18 | -A10)",
        "prover9_expression": "(market_release(Drug_Candidate_A) | -manufacturing_process_approved(Drug_Candidate_A))",
        "natural": "Either Drug Candidate A is released to the market or the manufacturing process for Drug Candidate A is not approved."
      },
      "(A19 → ¬A18)": {
        "formal": "(A19 → ¬A18)",
        "prover9": "(A19 -> -A18)",
        "prover9_expression": "(competitor_launch(Drug_X) -> -market_release(Drug_Candidate_A))",
        "natural": "If Competitor Drug X is launched, then Drug Candidate A is not released to the market."
      },
      "(A19 ∨ A20)": {
        "formal": "(A19 ∨ A20)",
        "prover9": "(A19 | A20)",
        "prover9_expression": "(competitor_launch(Drug_X) | generic_version_available(Drug_Candidate_A))",
        "natural": "Either Competitor Drug X is launched or a generic version of Drug Candidate A becomes available."
      },
      "(A2 → A3)": {
        "formal": "(A2 → A3)",
        "prover9": "(A2 -> A3)",
        "prover9_expression": "(clinical_trial_initiated(Drug_Candidate_A) -> clinical_trial_completed(Drug_Candidate_A))",
        "natural": "If clinical trials for Drug Candidate A are initiated, then clinical trials for Drug Candidate A are completed."
      },
      "(A2 ∨ (¬G → A1))": {
        "formal": "(A2 ∨ (¬G → A1))",
        "prover9": "(A2 | (-G -> A1))",
        "prover9_expression": "(clinical_trial_initiated(Drug_Candidate_A) | (-grant_awarded(Substance_Z) -> research_funded(Project_X)))",
        "natural": "Either clinical trials for Drug Candidate A are initiated or, if a grant for Substance Z is not awarded, then Project X receives research funding."
      },
      "(A20 → ¬A18)": {
        "formal": "(A20 → ¬A18)",
        "prover9": "(A20 -> -A18)",
        "prover9_expression": "(generic_version_available(Drug_Candidate_A) -> -market_release(Drug_Candidate_A))",
        "natural": "If a generic version of Drug Candidate A becomes available, then Drug Candidate A is not released to the market."
      },
      "(A21 ∨ (A20 → ¬A18))": {
        "formal": "(A21 ∨ (A20 → ¬A18))",
        "prover9": "(A21 | (A20 -> -A18))",
        "prover9_expression": "(price_reduction(Drug_Candidate_A) | (generic_version_available(Drug_Candidate_A) -> -market_release(Drug_Candidate_A)))",
        "natural": "Either the price of Drug Candidate A is reduced or, if a generic version of Drug Candidate A becomes available, then Drug Candidate A is not released to the market."
      },
      "(A22 → A21)": {
        "formal": "(A22 → A21)",
        "prover9": "(A22 -> A21)",
        "prover9_expression": "(sales_decline(Drug_Candidate_A) -> price_reduction(Drug_Candidate_A))",
        "natural": "If sales of Drug Candidate A decline, then the price of Drug Candidate A is reduced."
      },
      "(A22 ∨ A23)": {
        "formal": "(A22 ∨ A23)",
        "prover9": "(A22 | A23)",
        "prover9_expression": "(sales_decline(Drug_Candidate_A) | market_share_loss(Drug_Candidate_A))",
        "natural": "Either sales of Drug Candidate A decline or Drug Candidate A loses market share."
      },
      "(A23 → (A20 → ¬A18))": {
        "formal": "(A23 → (A20 → ¬A18))",
        "prover9": "(A23 -> (A20 -> -A18))",
        "prover9_expression": "(market_share_loss(Drug_Candidate_A) -> (generic_version_available(Drug_Candidate_A) -> -market_release(Drug_Candidate_A)))",
        "natural": "If Drug Candidate A loses market share, then, should a generic version of Drug Candidate A become available, Drug Candidate A is not released to the market."
      },
      "(A24 → (A8 ∨ A9))": {
        "formal": "(A24 → (A8 ∨ A9))",
        "prover9": "(A24 -> (A8 | A9))",
        "prover9_expression": "(research_shifted(Disease_Y) -> (human_trials_initiated(Drug_Candidate_B) | alternative_formulation_developed(Drug_Candidate_B)))",
        "natural": "If research focus shifts to Disease Y, then either human trials for Drug Candidate B are initiated or an alternative formulation for Drug Candidate B is developed."
      },
      "(A24 ∨ A25)": {
        "formal": "(A24 ∨ A25)",
        "prover9": "(A24 | A25)",
        "prover9_expression": "(research_shifted(Disease_Y) | new_indication_studied(Drug_Candidate_A))",
        "natural": "Either research focus shifts to Disease Y or a new indication for Drug Candidate A is studied."
      },
      "(A25 → (A8 ∨ A9))": {
        "formal": "(A25 → (A8 ∨ A9))",
        "prover9": "(A25 -> (A8 | A9))",
        "prover9_expression": "(new_indication_studied(Drug_Candidate_A) -> (human_trials_initiated(Drug_Candidate_B) | alternative_formulation_developed(Drug_Candidate_B)))",
        "natural": "If a new indication for Drug Candidate A is studied, then either human trials for Drug Candidate B are initiated or an alternative formulation for Drug Candidate B is developed."
      },
      "(A26 → A24)": {
        "formal": "(A26 → A24)",
        "prover9": "(A26 -> A24)",
        "prover9_expression": "(breakthrough_finding(Disease_Y) -> research_shifted(Disease_Y))",
        "natural": "If a breakthrough finding for Disease Y occurs, then research focus shifts to Disease Y."
      },
      "(A26 ∨ A27)": {
        "formal": "(A26 ∨ A27)",
        "prover9": "(A26 | A27)",
        "prover9_expression": "(breakthrough_finding(Disease_Y) | existing_drug_repurposed(Drug_Candidate_A))",
        "natural": "Either a breakthrough finding for Disease Y occurs or Drug Candidate A is repurposed for an existing condition."
      },
      "(A27 → A25)": {
        "formal": "(A27 → A25)",
        "prover9": "(A27 -> A25)",
        "prover9_expression": "(existing_drug_repurposed(Drug_Candidate_A) -> new_indication_studied(Drug_Candidate_A))",
        "natural": "If Drug Candidate A is repurposed for an existing condition, then a new indication for Drug Candidate A is studied."
      },
      "(A28 ∨ (A27 → A25))": {
        "formal": "(A28 ∨ (A27 → A25))",
        "prover9": "(A28 | (A27 -> A25))",
        "prover9_expression": "(partnership_formed(Company_B) | (existing_drug_repurposed(Drug_Candidate_A) -> new_indication_studied(Drug_Candidate_A)))",
        "natural": "Either a partnership with Company B is formed or, if Drug Candidate A is repurposed for an existing condition, then a new indication for Drug Candidate A is studied."
      },
      "(A29 ∨ ¬A28)": {
        "formal": "(A29 ∨ ¬A28)",
        "prover9": "(A29 | -A28)",
        "prover9_expression": "(licensing_agreement_signed(Company_B) | -partnership_formed(Company_B))",
        "natural": "Either a licensing agreement with Company B is signed or a partnership with Company B is not formed."
      },
      "(A3 → A4)": {
        "formal": "(A3 → A4)",
        "prover9": "(A3 -> A4)",
        "prover9_expression": "(clinical_trial_completed(Drug_Candidate_A) -> regulatory_approval_granted(Drug_Candidate_A))",
        "natural": "If clinical trials for Drug Candidate A are completed, then regulatory approval for Drug Candidate A is granted."
      },
      "(A3 → A5)": {
        "formal": "(A3 → A5)",
        "prover9": "(A3 -> A5)",
        "prover9_expression": "(clinical_trial_completed(Drug_Candidate_A) -> side_effects_observed(Drug_Candidate_A))",
        "natural": "If clinical trials for Drug Candidate A are completed, then side effects for Drug Candidate A are observed."
      },
      "(A3 → ¬A4)": {
        "formal": "(A3 → ¬A4)",
        "prover9": "(A3 -> -A4)",
        "prover9_expression": "(clinical_trial_completed(Drug_Candidate_A) -> -regulatory_approval_granted(Drug_Candidate_A))",
        "natural": "If clinical trials for Drug Candidate A are completed, then regulatory approval for Drug Candidate A is not granted."
      },
      "(A30 → (A13 → G))": {
        "formal": "(A30 → (A13 → G))",
        "prover9": "(A30 -> (A13 -> G))",
        "prover9_expression": "(research_published(Substance_Z) -> (compound_discovered(Substance_Z) -> grant_awarded(Substance_Z)))",
        "natural": "If research on Substance Z is published, then, if Substance Z is discovered, a grant for Substance Z is awarded."
      },
      "(A30 ∨ A31)": {
        "formal": "(A30 ∨ A31)",
        "prover9": "(A30 | A31)",
        "prover9_expression": "(research_published(Substance_Z) | conference_presentation(Substance_Z))",
        "natural": "Either research on Substance Z is published or a conference presentation on Substance Z is made."
      },
      "(A31 → (A13 → G))": {
        "formal": "(A31 → (A13 → G))",
        "prover9": "(A31 -> (A13 -> G))",
        "prover9_expression": "(conference_presentation(Substance_Z) -> (compound_discovered(Substance_Z) -> grant_awarded(Substance_Z)))",
        "natural": "If a conference presentation on Substance Z is made, then, if Substance Z is discovered, a grant for Substance Z is awarded."
      },
      "(A32 → (A30 ∨ A31))": {
        "formal": "(A32 → (A30 ∨ A31))",
        "prover9": "(A32 -> (A30 | A31))",
        "prover9_expression": "(peer_review_completed(Substance_Z) -> (research_published(Substance_Z) | conference_presentation(Substance_Z)))",
        "natural": "If peer review for Substance Z is completed, then either research on Substance Z is published or a conference presentation on Substance Z is made."
      },
      "(A33 → A34)": {
        "formal": "(A33 → A34)",
        "prover9": "(A33 -> A34)",
        "prover9_expression": "(patent_challenged(Substance_Z) -> legal_dispute_initiated(Substance_Z))",
        "natural": "If the patent for Substance Z is challenged, then a legal dispute over Substance Z is initiated."
      },
      "(A33 → ¬A34)": {
        "formal": "(A33 → ¬A34)",
        "prover9": "(A33 -> -A34)",
        "prover9_expression": "(patent_challenged(Substance_Z) -> -legal_dispute_initiated(Substance_Z))",
        "natural": "If the patent for Substance Z is challenged, then a legal dispute over Substance Z is not initiated."
      },
      "(A5 → A4)": {
        "formal": "(A5 → A4)",
        "prover9": "(A5 -> A4)",
        "prover9_expression": "(side_effects_observed(Drug_Candidate_A) -> regulatory_approval_granted(Drug_Candidate_A))",
        "natural": "If side effects for Drug Candidate A are observed, then regulatory approval for Drug Candidate A is granted."
      },
      "(A6 → A7)": {
        "formal": "(A6 → A7)",
        "prover9": "(A6 -> A7)",
        "prover9_expression": "(preclinical_stage_initiated(Drug_Candidate_B) -> animal_testing_completed(Drug_Candidate_B))",
        "natural": "If the preclinical stage for Drug Candidate B is initiated, then animal testing for Drug Candidate B is completed."
      },
      "(A6 ∨ G)": {
        "formal": "(A6 ∨ G)",
        "prover9": "(A6 | G)",
        "prover9_expression": "(preclinical_stage_initiated(Drug_Candidate_B) | grant_awarded(Substance_Z))",
        "natural": "Either the preclinical stage for Drug Candidate B is initiated or a grant for Substance Z is awarded."
      },
      "(A8 → ¬A7)": {
        "formal": "(A8 → ¬A7)",
        "prover9": "(A8 -> -A7)",
        "prover9_expression": "(human_trials_initiated(Drug_Candidate_B) -> -animal_testing_completed(Drug_Candidate_B))",
        "natural": "If human trials for Drug Candidate B are initiated, then animal testing for Drug Candidate B is not completed."
      },
      "(A8 ∨ A9)": {
        "formal": "(A8 ∨ A9)",
        "prover9": "(A8 | A9)",
        "prover9_expression": "(human_trials_initiated(Drug_Candidate_B) | alternative_formulation_developed(Drug_Candidate_B))",
        "natural": "Either human trials for Drug Candidate B are initiated or an alternative formulation for Drug Candidate B is developed."
      },
      "(A9 → ¬A7)": {
        "formal": "(A9 → ¬A7)",
        "prover9": "(A9 -> -A7)",
        "prover9_expression": "(alternative_formulation_developed(Drug_Candidate_B) -> -animal_testing_completed(Drug_Candidate_B))",
        "natural": "If an alternative formulation for Drug Candidate B is developed, then animal testing for Drug Candidate B is not completed."
      },
      "(¬(A10 → A11) → A12)": {
        "formal": "(¬(A10 → A11) → A12)",
        "prover9": "(-(A10 -> A11) -> A12)",
        "prover9_expression": "(-(manufacturing_process_approved(Drug_Candidate_A) -> mass_production_begun(Drug_Candidate_A)) -> manufacturing_process_revised(Drug_Candidate_A))",
        "natural": "If it is not the case that the manufacturing process for Drug Candidate A being approved leads to mass production of Drug Candidate A beginning, then the manufacturing process for Drug Candidate A is revised."
      },
      "(¬(A13 → G) → A14)": {
        "formal": "(¬(A13 → G) → A14)",
        "prover9": "(-(A13 -> G) -> A14)",
        "prover9_expression": "(-(compound_discovered(Substance_Z) -> grant_awarded(Substance_Z)) -> patent_filed(Substance_Z))",
        "natural": "If it is not the case that Substance Z being discovered leads to a grant for Substance Z being awarded, then a patent for Substance Z is filed."
      },
      "(¬(A13 → G) → A15)": {
        "formal": "(¬(A13 → G) → A15)",
        "prover9": "(-(A13 -> G) -> A15)",
        "prover9_expression": "(-(compound_discovered(Substance_Z) -> grant_awarded(Substance_Z)) -> patent_approved(Substance_Z))",
        "natural": "If it is not the case that Substance Z being discovered leads to a grant for Substance Z being awarded, then the patent for Substance Z is approved."
      },
      "(¬(A13 → G) → ¬A14)": {
        "formal": "(¬(A13 → G) → ¬A14)",
        "prover9": "(-(A13 -> G) -> -A14)",
        "prover9_expression": "(-(compound_discovered(Substance_Z) -> grant_awarded(Substance_Z)) -> -patent_filed(Substance_Z))",
        "natural": "If it is not the case that Substance Z being discovered leads to a grant for Substance Z being awarded, then a patent for Substance Z is not filed."
      },
      "(¬(A3 → A4) → A16)": {
        "formal": "(¬(A3 → A4) → A16)",
        "prover9": "(-(A3 -> A4) -> A16)",
        "prover9_expression": "(-(clinical_trial_completed(Drug_Candidate_A) -> regulatory_approval_granted(Drug_Candidate_A)) -> clinical_trial_suspended(Drug_Candidate_A))",
        "natural": "If it is not the case that clinical trials for Drug Candidate A being completed leads to regulatory approval for Drug Candidate A being granted, then clinical trials for Drug Candidate A are suspended."
      },
      "(¬(A3 → A4) → ¬A16)": {
        "formal": "(¬(A3 → A4) → ¬A16)",
        "prover9": "(-(A3 -> A4) -> -A16)",
        "prover9_expression": "(-(clinical_trial_completed(Drug_Candidate_A) -> regulatory_approval_granted(Drug_Candidate_A)) -> -clinical_trial_suspended(Drug_Candidate_A))",
        "natural": "If it is not the case that clinical trials for Drug Candidate A being completed leads to regulatory approval for Drug Candidate A being granted, then clinical trials for Drug Candidate A are not suspended."
      },
      "(¬(A8 ∨ A9) → A10)": {
        "formal": "(¬(A8 ∨ A9) → A10)",
        "prover9": "(-(A8 | A9) -> A10)",
        "prover9_expression": "(-(human_trials_initiated(Drug_Candidate_B) | alternative_formulation_developed(Drug_Candidate_B)) -> manufacturing_process_approved(Drug_Candidate_A))",
        "natural": "If neither human trials for Drug Candidate B are initiated nor an alternative formulation for Drug Candidate B is developed, then the manufacturing process for Drug Candidate A is approved."
      },
      "(¬(¬(A3 → A4) → ¬A16) → A17)": {
        "formal": "(¬(¬(A3 → A4) → ¬A16) → A17)",
        "prover9": "(-(-(A3 -> A4) -> -A16) -> A17)",
        "prover9_expression": "(-(-(clinical_trial_completed(Drug_Candidate_A) -> regulatory_approval_granted(Drug_Candidate_A)) -> -clinical_trial_suspended(Drug_Candidate_A)) -> investigation_launched(Drug_Candidate_A))",
        "natural": "If it is not the case that the failure of clinical trials for Drug Candidate A being completed to lead to regulatory approval for Drug Candidate A being granted results in clinical trials for Drug Candidate A not being suspended, then an investigation into Drug Candidate A is launched."
      },
      "(¬A32 → A33)": {
        "formal": "(¬A32 → A33)",
        "prover9": "(-A32 -> A33)",
        "prover9_expression": "(-peer_review_completed(Substance_Z) -> patent_challenged(Substance_Z))",
        "natural": "If peer review for Substance Z is not completed, then the patent for Substance Z is challenged."
      },
      "(¬G → A1)": {
        "formal": "(¬G → A1)",
        "prover9": "(-G -> A1)",
        "prover9_expression": "(-grant_awarded(Substance_Z) -> research_funded(Project_X))",
        "natural": "If a grant for Substance Z is not awarded, then Project X receives research funding."
      },
      "A13": {
        "formal": "A13",
        "prover9": "A13",
        "prover9_expression": "compound_discovered(Substance_Z)",
        "natural": "Substance Z is discovered."
      },
      "A32": {
        "formal": "A32",
        "prover9": "A32",
        "prover9_expression": "peer_review_completed(Substance_Z)",
        "natural": "Peer review for Substance Z is completed."
      },
      "G": {
        "formal": "G",
        "prover9": "G",
        "prover9_expression": "grant_awarded(Substance_Z)",
        "natural": "A grant for Substance Z is awarded."
      },
      "¬A1": {
        "formal": "¬A1",
        "prover9": "-A1",
        "prover9_expression": "-research_funded(Project_X)",
        "natural": "Project X does not receive research funding."
      },
      "¬A10": {
        "formal": "¬A10",
        "prover9": "-A10",
        "prover9_expression": "-manufacturing_process_approved(Drug_Candidate_A)",
        "natural": "The manufacturing process for Drug Candidate A is not approved."
      },
      "¬A12": {
        "formal": "¬A12",
        "prover9": "-A12",
        "prover9_expression": "-manufacturing_process_revised(Drug_Candidate_A)",
        "natural": "The manufacturing process for Drug Candidate A is not revised."
      },
      "¬A17": {
        "formal": "¬A17",
        "prover9": "-A17",
        "prover9_expression": "-investigation_launched(Drug_Candidate_A)",
        "natural": "An investigation into Drug Candidate A is not launched."
      },
      "¬A18": {
        "formal": "¬A18",
        "prover9": "-A18",
        "prover9_expression": "-market_release(Drug_Candidate_A)",
        "natural": "Drug Candidate A is not released to the market."
      },
      "¬A2": {
        "formal": "¬A2",
        "prover9": "-A2",
        "prover9_expression": "-clinical_trial_initiated(Drug_Candidate_A)",
        "natural": "Clinical trials for Drug Candidate A are not initiated."
      },
      "¬A21": {
        "formal": "¬A21",
        "prover9": "-A21",
        "prover9_expression": "-price_reduction(Drug_Candidate_A)",
        "natural": "The price of Drug Candidate A is not reduced."
      },
      "¬A28": {
        "formal": "¬A28",
        "prover9": "-A28",
        "prover9_expression": "-partnership_formed(Company_B)",
        "natural": "A partnership with Company B is not formed."
      },
      "¬A29": {
        "formal": "¬A29",
        "prover9": "-A29",
        "prover9_expression": "-licensing_agreement_signed(Company_B)",
        "natural": "A licensing agreement with Company B is not signed."
      },
      "¬A3": {
        "formal": "¬A3",
        "prover9": "-A3",
        "prover9_expression": "-clinical_trial_completed(Drug_Candidate_A)",
        "natural": "Clinical trials for Drug Candidate A are not completed."
      },
      "¬A33": {
        "formal": "¬A33",
        "prover9": "-A33",
        "prover9_expression": "-patent_challenged(Substance_Z)",
        "natural": "The patent for Substance Z is not challenged."
      },
      "¬A6": {
        "formal": "¬A6",
        "prover9": "-A6",
        "prover9_expression": "-preclinical_stage_initiated(Drug_Candidate_B)",
        "natural": "The preclinical stage for Drug Candidate B is not initiated."
      },
      "¬A7": {
        "formal": "¬A7",
        "prover9": "-A7",
        "prover9_expression": "-animal_testing_completed(Drug_Candidate_B)",
        "natural": "Animal testing for Drug Candidate B is not completed."
      }
    }
  }
}